PMCPA Case Analysis

Over 2,000 real rulings β€” analysed for what they mean to your team. Published every day.

All Cases PMCPA Case of the Week PMCPA Cases

Showing 1914 cases

2022
CASE
AUTH/3665/6/22 Novartis Pharmaceuticals UK

Novartis breached Clause 6.1 and 5.1 over β€˜1st line’ Entresto guideline claim lacking HFrEF definition (AUTH/3665/6/22)

Novartis’ Entresto HCP website claim that national guidelines support 1st line use in chronic HFrEF was ruled insufficiently complete for a broad…

2022
CASE
AUTH/3662/6/22 Novartis Pharmaceuticals UK

Novartis: MailOnline MS disease-awareness articleβ€”share-button templates not certified (AUTH/3662/6/22)

Novartis certified a MailOnline MS disease-awareness article, but the PMCPA found the social share templates generated by share buttons weren’t certified. Breach…

2022
CASE
AUTH/3713/11/22 Dr Falk Pharma

PMCPA AUTH/3713/11/22: Tillotts Pharma v Dr Falk Pharma (Budenofalk digital ad not withdrawn)

Dr Falk was ruled in breach of Clause 5.1 after a Budenofalk digital ad remained in use 12 weeks after agreeing to…

2021
CASE
Novartis Pharmaceuticals UK

AAA website: out-of-date Northern Ireland licensing statement for Pluvicto led to Code breaches

AAA’s RLT Hub stated Pluvicto was not licensed in Northern Ireland after EMA approval. PMCPA found the statement inaccurate/out-of-date and criticised website…

2023
CASE
AUTH/3759/4/23 Boehringer Ingelheim ⭐ Case of the Week

AUTH/3759/4/23: Boehringer Ingelheim clinical trial recruitment flyer at BSG Conference 2023 – No breach

Anonymous complaint alleged a Phase 2/3 sarcoma trial flyer in conference bags was pre-licence promotion and inappropriately distributed. Panel found the content…

2023
CASE
AUTH/3760/4/23 GlaxoSmithKline

GSK press release on COVID-19 vaccine efficacy ruled misleading (RRR presented without sufficient context) – AUTH/3760/4/23

A member of the public challenged GSK’s press release for quoting vaccine β€œefficacy” percentages without absolute risk/context. PMCPA ruled the presentation could…

2023
CASE
AUTH/3775/6/23 AstraZeneca

AstraZeneca: UK employee β€˜liked’ US LinkedIn post linking to Breztri press release – POM promotion to the public (AUTH/3775/6/23)

A UK-based AstraZeneca employee β€˜liked’ a US colleague’s LinkedIn post linking to a Breztri press release. The Panel ruled this proactively disseminated…

2023
CASE
AUTH/3781/6/23 GlaxoSmithKline

GSK fined for ambiguous Trelegy website claim implying significant exacerbation reduction vs unnamed triple therapy (AUTH/3781/6/23)

PMCPA ruled GSK’s Trelegy HCP webpage claim β€œgreater exacerbation reduction vs another single-inhaler triple therapy” was ambiguous and misleading, implying significance without…

2023
CASE
AUTH/3820/9/23 Daiichi-Sankyo UK

AUTH/3820/9/23: Complainant v Daiichi Sankyo (AI recording of HCP calls) – No breach

Anonymous complaint alleged Daiichi Sankyo covertly recorded HCP calls using an AI tool. Panel found no evidence of covert recording and accepted…

2015
CASE
Novo Nordisk ⭐ Case of the Week

Novo Nordisk: multiple failures in transfers of value disclosure (2015–2022) led to Clause 2 breach

Novo Nordisk was ruled in breach for failures to disclose, late disclosure, and inaccurate/misplaced reporting of transfers of value to HCOs and…

2023
CASE
AUTH/3868/12/23 Rosemont Pharmaceuticals

AUTH/3868/12/23: Rosemont Pharmaceuticals – LinkedIn post and alleged public access to POM webpage (No breach)

Complaint alleged a Rosemont LinkedIn post and website content promoted a specific POM to the public and lacked certification. Panel found the…

2024
CASE
AUTH/3891/4/24 AbbVie

AbbVie breached Clause 8.5 after failing to recertify an AbbVie Pro landing page within two years (AUTH/3891/4/24)

AbbVie failed to recertify an AbbVie Pro β€œOncology Focus Area” landing page within the required two-year interval. PMCPA found a breach of…

2024
CASE
AUTH/3880/2/24 GlaxoSmithKline

AUTH/3880/2/24: Complainant v GSK β€” LinkedIn acquisition post referencing investigational AIO-001 (No breach after appeal)

Complaint alleged pre-licence promotion via a LinkedIn post linking to a GSK press release about Aiolos Bio acquisition and AIO-001 in asthma.…

2021
CASE
GlaxoSmithKline

GSK COPD decision support tool: sponsorship declaration not shown from the outset (Clause 25.3)

GSK-sponsored COPD decision support tool lacked a prominent sponsorship declaration at the outset of the homepage after sponsorship ended. PMCPA ruled a…

2019
CASE
Bristol-Myers Squibb Pharmaceuticals

Pfizer and Bristol-Myers Squibb: Eliquis promotion on Pulse email and microsite found misleading and missing prescribing information

A UK health professional complained about a Pulse promotional email and linked Eliquis VTE webpages. The email lacked prescribing information and a…

Ask questions about any PMCPA case

Anzal, our PMCPA rulings expert, has knowledge of over 2,000 published cases β€” ask about precedents, clauses, and how they apply to your situation.

⭐ Flagship Programme

AQP Flagship Path — the complete UK ABPI signatory programme

12 modules. 12 weeks. Final Signatory readiness. The industry standard for ABPI Code signatories — £995 + VAT.

Enrol — AQP Path Learn more

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week β€” free.

Subscribe Free
🎓 AQP Training